| Literature DB >> 33921798 |
Ana-Maria Udrea1,2, Andra Dinache1, Jean-Marie Pagès3, Ruxandra Angela Pirvulescu4,5.
Abstract
Multidrug resistance of bacteria is a worrying concern in the therapeutic field and an alternative method to combat it is designing new efflux pump inhibitors (EPIs). This article presents a molecular study of two quinazoline derivatives, labelled BG1189 and BG1190, proposed as EPIs. In silico approach investigates the pharmacodynamic and pharmacokinetic profile of BG1189 and BG1190Entities:
Keywords: AcrAB-TolC pump; FTIR spectroscopy; UV-Vis spectroscopy; efflux pump inhibitor; molecular docking; multidrug resistance (MDR); quinazoline
Mesh:
Substances:
Year: 2021 PMID: 33921798 PMCID: PMC8073189 DOI: 10.3390/molecules26082374
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Drug-like rules Lipinski, Ghose and Veber validation for molecules BG1189 and BG1190.
| Molecule | BG1190 | BG1189 | ||||
|---|---|---|---|---|---|---|
| Validate | Molecular Descriptors | Value | Validate | Molecular Descriptors | Value | |
| Lipinski | Yes | MW ≤ 500 | 289.31 | Yes | MW ≤ 500 | 277.30 |
| MlogP | 1.04 | MlogP | 0.37 | |||
| Acc ≤ 10 | 5 | Acc ≤ 10 | 5 | |||
| Don ≤ 5 | 1 | Don ≤ 5 | 1 | |||
| Ghose | Yes | 160 ≤ MW ≤480 | 289.31 | Yes | 160 ≤ MW ≤ 480 | 277.30 |
| −0.4 ≤ WlogP | 0.91 | -0.4 ≤ WlogP | 1.15 | |||
| 40 ≤ MR ≤ 130 | 81.07 | 40 ≤ MR ≤ 130 | 74.46 | |||
| 20 ≤ atoms ≤ 70 | 38 | 20 ≤ atoms ≤ 70 | 37 | |||
| Veber | Yes | Rotatable bonds ≤ 10 | 4 | Yes | Rotatable bonds ≤ 10 | 5 |
| TPSA ≤ 140 Å2 | 78.44 Å2 | TPSA ≤ 140 Å2 | 78.44 Å2 | |||
Predicted ADMET results for BG1189 and BG1190 quinazoline derivatives compared with predicted ADMET values of norfloxacin.
| Model Name | Predicted Value BG1190 | Predicted Value BG1189 | Predicted Value Norfloxacin | Unit |
|---|---|---|---|---|
| Water Solubility | −1.992 | −1.549 | −3.176 | log mol/L |
| Caco2 Permeability | 0.76 | 0.597 | 1.242 | log Papp in 10−6 cm/s |
| Intestinal Absorption (Human) | 87.391 | 78.106 | 86.904 | % Absorbed |
| VDss (Human) | 0.909 | 0.84 | 0.064 | log L/kg |
| Fraction Unbound (Human) | 0.713 | 0.612 | 0.462 | Fu |
| Total Clearance | 0.811 | 0.594 | 0.366 | log ml/min/kg |
| Renal OCT2 Substrate | Yes | No | No | Yes/No |
| hERG I Inhibitor | No | No | No | Yes/No |
| hERG II Inhibitor | Yes | Yes | No | Yes/No |
| Oral Rat Acute Toxicity (LD50) | 2.55 | 2.541 | 2.217 | mol/kg |
| Hepatotoxicity | Yes | Yes | Yes | Yes/No |
Molecular docking results for quinazoline derivatives BG1189 and BG1190 on multidrug efflux pump subunit AcrB (PDB code: 5NC5). AA residues in h-bound with quinazoline derivatives are underlined.
| Multidrug Efflux Pump Subunit AcrB (PDB Code: 5NC5) | |
|---|---|
| AA Residues from Allosteric Situs of AcrB Subunit. | Met573; Phe617; Phe628; Phe666; Leu668. |
| Lowest EFEB BG1190 | −8.21 kcal/mol |
| AA from the Run with Lowest EFEB of BG1990 | Gln34; Pro36; Thr37; Ala39; Ser134; Ser135; |
| Lowest EFEB BG1189 | −7.40 kcal/mol |
| AA from the Run with Lowest EFEB of BG1989 | |
Figure 1AcrB subunit of the multidrug efflux pump chain B (PDB code: 5NC5). (i) Experimental data—(a) AA in close contact with puromycin (antibiotic crystallized with the protein); (b) puromycin allosteric binding situs. (ii) Predicted data—(c,e) AA in close contact with BG1189 respectively BG1190; (d,f)—BG1189 respectively BG1190 interacting with pore domains of AcrB subunit. (a,c,e) Light green: van der Waals interactions; green: conventional hydrogen bond, grey: carbon hydrogen bond; red: unfavorable acceptor–acceptor interaction; dark pink: Pi–Pi T-shaped interaction; light pink: Pi–Alkyl interactions; (b,d,f) alpha helices of the protein are represented in red color, beta sheets in blue, turns in green, and random coil in grey. Images were obtained using Discovery Studio Visualizer [36].
Figure 2Time evolution of absorption spectra of quinazoline derivatives: (a) BG1189 and (b) BG1190. Solutions prepared in ultrapure water at 10−3 M; kept in dark, at 22 °C.
Figure 3Time evolution of absorption spectra of quinazoline derivatives: (a) BG1189 and (b) BG1190. Solutions prepared in dimethyl sulfoxide (DMSO) at 10−3 M; kept in dark, at 22 °C.
Figure 4Influence of the storage temperature (4, 22 and 37 °C) on the absorption spectra of: (a) BG1189 and (b) BG1190. Solutions prepared in ultrapure water at 10−3 M, kept in dark.
Figure 5Influence of the illumination conditions on the absorption spectra of: (a) BG1189 and (b) BG1190. Solutions prepared in ultrapure water at 10−3 M, kept at 22 °C.
Figure 6Laser induced modifications of the absorption spectra of: (a) BG1189 and (b) BG1190. Solutions prepared in ultrapure water at 10−3 M. Laser irradiation conditions: E = 6 mJ, λ = 266 nm.
Figure 7FTIR spectra of the unirradiated and 1 h irradiated BG1189 10−3 M solutions in water.
Figure 8FTIR spectra of the unirradiated and 1 h irradiated BG1190 10−3 M solutions in water.
Figure 9Chemical structures of quinazoline derivatives: (a) BG1189 and (b) BG1190.